# US 2012/0269859 A1 · Multimer of extracellular domain of cell surface functional molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269859 A1
- Document ID: US20120269859A1
- Status: Published application
- Kind: A1
- Application number: 13/486,189
- Filed: 2012-06-01
- Published: 2012-10-25
- Earliest claimed: 2006-03-03
- Assignees: Ono Pharmaceutical Co., Ltd.
- Inventors: Nagahiro Minato; Yoshimasa Tanaka; Shiro Shibayama
- Web page: https://patentgrep.com/patent/US20120269859A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/08: for Pneumocystis carinii
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A multimer comprising 2 to 10 extracellular domains of Programmed Cell Death-Ligand 1 (PD-L1).

### Claim 21 (depends on 20)

The multimer according to claim 20, wherein the extracellular domains of PD-L1 are serially-concatenated directly or with peptide linkers.

### Claim 22 (depends on 20)

The multimer according to claim 20, wherein each of the extracellular domains of PD-L1 comprises a region selected from (a) and (b):
(a) residues 1-238 or residues 18-230 of full-length human PD-L1; and
(b) residues 1-237 or residues 18-229 of full-length mouse PD-L1.

### Claim 23 (depends on 22)

The multimer according to claim 22, wherein 1 to 3 amino acid(s) in each of the extracellular domains of PD-L1 is/are substituted by other amino acid(s).

### Claim 24 (depends on 20)

The multimer according to claim 20, wherein the multimer is a tetramer.

### Claim 25 (depends on 20)

The multimer according to claim 20, wherein each of the extracellular domains of PD-L1 is serially-concatenated with peptide linkers.

### Claim 26 (depends on 20)

The multimer according to claim 20, wherein each peptide linker comprises 2 to 15 amino acids.

### Claim 27 (depends on 20)

The multimer according to claim 20, wherein the extracellular domains of PD-L1 are bound to a carrier via a non-peptide linker.

### Claim 28 (depends on 27)

The multimer according to claim 27, wherein the carrier is an avidin, streptavidin or a derivative thereof and the non-peptide linker is a biotin.

### Claim 29 (depends on 26)

The multimer according to claim 26, comprising the amino acid sequence of SEQ ID NO: 5 or 7.

### Claim 30 (depends on 20)

A pharmaceutical composition comprising the multimer according to claim 20 as an active ingredient.

### Claim 31 (depends on 30)

The pharmaceutical composition according to claim 30, which is a preventive and/or therapeutic agent for cancers, cancer metastasis, immune deficiency syndrome or infectious diseases.

### Claim 32 (depends on 20)

An agent comprising the multimer according to claim 20 and at least one ingredient selected from the group consisting of chemotherapy drugs, cancer treatment adjuvants, immunomodulators, cancer antigens, antiviral agents, antibiotic preparations, antimicrobials, fungal treatments and vaccines.

### Claim 33 (depends on 20)

A Programmed Cell Death-1 (PD-1) detection reagent comprising the multimer according to claim 20.
